Literature DB >> 12183159

Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine.

Terry B Strom1, Loren J Field, Manfred Ruediger.   

Abstract

The therapeutic use of stem cells is a popular topic that is often in the news. Stem cells are of particular relevance to the transplant community, as stem cell-based therapies will probably be derived from allogeneic sources. Stem cells may be obtained from somatic (adult) cell or embryonic cell origin. The ability to establish stem cell lines in vitro means that we can standardize therapeutic grafting applications, which is a prerequisite for the widespread application of stem cell therapy. This attribute also means that we can produce large batches of allogeneic terminally differentiated cells, which can be administered to patients. Three important barriers to the deployment of this therapy currently exist; in addition to the many ethical issues facing the widespread use of stem cell therapy, it is also important to develop methods to derive pure terminally differentiated cells for transplantation and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot be justified for many potential applications.

Entities:  

Mesh:

Year:  2002        PMID: 12183159     DOI: 10.1016/s0952-7915(02)00387-4

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  6 in total

1.  Inositol-1,4,5-trisphosphate-mediated spontaneous activity in mouse embryonic stem cell-derived cardiomyocytes.

Authors:  Nidhi Kapur; Kathrin Banach
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

2.  Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts.

Authors:  Wangde Dai; Loren J Field; Michael Rubart; Sean Reuter; Sharon L Hale; Robert Zweigerdt; Ralph E Graichen; Gregory L Kay; Aarne J Jyrala; Alan Colman; Bruce P Davidson; Martin Pera; Robert A Kloner
Journal:  J Mol Cell Cardiol       Date:  2007-07-14       Impact factor: 5.000

3.  Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2006-03-07       Impact factor: 4.599

4.  Pilot study: bone marrow stem cells as a treatment for dogs with chronic spinal cord injury.

Authors:  Carlos Alberto Palmeira Sarmento; Marcio Nogueira Rodrigues; Renato Zonzini Bocabello; Andrea Maria Mess; Maria Angelica Miglino
Journal:  Regen Med Res       Date:  2014-12-12

Review 5.  The impact of immune response on endochondral bone regeneration.

Authors:  A Longoni; L Knežević; K Schepers; H Weinans; A J W P Rosenberg; D Gawlitta
Journal:  NPJ Regen Med       Date:  2018-11-29

Review 6.  Cell replacement therapy and the evasion of destructive immunity.

Authors:  Paul J Fairchild; Nathan J Robertson; Siân Cartland; Kathleen F Nolan; Herman Waldmann
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.